ArticleMolecular cancer therapeutics2021
Functional Characterization of Brain Tumor-Initiating Cells and Establishment of GBM Preclinical Models that Incorporate Heterogeneity, Therapy, and Sex Differences.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- Multi-sampling allows intra-tumoral heterogeneity querying and vulnerability profiling in glioblastoma.Neuro-oncology · 2026Article
- Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme.Communications medicine · 2026Article
- Virtual Clinical Trials of BMP4 Differentiation Therapy: Digital Twins to Aid Successful Glioblastoma Trial Design.bioRxiv : the preprint server for biology · 2025Article
- TurboID-Mediated Profiling of Glioblastoma-Derived Extracellular Vesicle Cargo Proteins.Journal of extracellular vesicles · 2025Article
- GLIO-Select: Machine Learning-Based Feature Selection and Weighting of Tissue and Serum Proteomic and Metabolomic Data Uncovers Sex Differences in Glioblastoma.International journal of molecular sciences · 2025Article
- USP9X deubiquitinates TRRAP to promote glioblastoma cell proliferation and migration and M2 macrophage polarization.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Solid cancer-directed CAR T cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1.Molecular therapy. Oncology · 2024Article
- Therapeutic potential and impact of nanoengineered patient-derived mesenchymal stem cells in a murine resection and recurrence model of human glioblastoma.Bioengineering & translational medicine · 2024Article
- Cell-specific cross-talk proteomics reveals cathepsin B signaling as a driver of glioblastoma malignancy near the subventricular zone.Science advances · 2024Article
- From the Operating Room to the Laboratory: Role of the Neuroscience Tissue Biorepository in the Clinical, Translational, and Basic Science Research Pipeline.Mayo Clinic proceedings · 2024Article
- Stabilization of KPNB1 by deubiquitinase USP7 promotes glioblastoma progression through the YBX1-NLGN3 axis.Journal of experimental & clinical cancer research : CR · 2024Article
- Behavior of glioblastoma brain tumor stem cells following a suborbital rocket flight: reaching the "edge" of outer space.NPJ microgravity · 2023Article
- Magnetic resonance imaging findings of intracranial extraventricular ependymoma: A retrospective multi-center cohort study of 114 cases.Cancer medicine · 2023Article
- Perivascular invasion of primary human glioblastoma cells in organotypic human brain slices: human cells migrating in human brain.Journal of neuro-oncology · 2023Article
- Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibit moderate effect on normal stem cells growth.Investigational new drugs · 2023Article
- Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibiting moderate effect on normal stem cells growth.Research square · 2023Article
- SARS-CoV2 entry factors are expressed in primary human glioblastoma and recapitulated in cerebral organoid models.Journal of neuro-oncology · 2023Article
- Advances in computational and translational approaches for malignant glioma.Frontiers in physiology · 2023Review
- Article
- The Next Frontier in Health Disparities-A Closer Look at Exploring Sex Differences in Glioma Data and Omics Analysis, from Bench to Bedside and Back.Biomolecules · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Cesar A GarciaDepartment of Neurosurgery, Mayo Clinic, Jacksonville, Florida.ORCID 0000-0002-8268-3356
Adip G BhargavDepartment of Neurosurgery, Mayo Clinic, Jacksonville, Florida.ORCID 0000-0003-4754-9984
Mieu BrooksDepartment of Neurosurgery, Mayo Clinic, Jacksonville, Florida.
Paola Suárez-MeadeDepartment of Neurosurgery, Mayo Clinic, Jacksonville, Florida.
Sujan K MondalDepartment of Neurosurgery, Mayo Clinic, Jacksonville, Florida.
Natanael ZarcoDepartment of Neurosurgery, Mayo Clinic, Jacksonville, Florida.
Karim ReFaeyDepartment of Neurosurgery, Mayo Clinic, Jacksonville, Florida.
Mark JentoftDepartment of Pathology, Mayo Clinic, Jacksonville, Florida.
Erik H MiddlebrooksDepartment of Neurosurgery, Mayo Clinic, Jacksonville, Florida.
Matija SnuderlDepartment of Pathology, NYU Langone Health, New York, New York.
Anna CarranoDepartment of Neurosurgery, Mayo Clinic, Jacksonville, Florida.ORCID 0000-0002-6773-3108
Hugo Guerrero-CazaresDepartment of Neurosurgery, Mayo Clinic, Jacksonville, Florida.ORCID 0000-0003-1307-719X
Paula SchiapparelliDepartment of Neurosurgery, Mayo Clinic, Jacksonville, Florida.
Rachel Sarabia-EstradaDepartment of Neurosurgery, Mayo Clinic, Jacksonville, Florida.ORCID 0000-0002-6836-5554
Alfredo Quiñones-HinojosaDepartment of Neurosurgery, Mayo Clinic, Jacksonville, Florida. Quinones-Hinojosa.Alfredo@mayo.edu.
Jacksonville College · USNYU Langone Health · US
Funding
Intra-Operative, Label-Free Detection of Brain Cancer Infiltration with Quantitative Optical ImagingR01CA200399 · NCI · JOHNS HOPKINS UNIVERSITY · PI LI, XINGDE, QUINONES-HINOJOSA, ALFREDO · 2016 to 2020
$3.0MRole of NKCC1 on Brain Tumor Stem Cell Migration After EGF and Slit-2 StimulationR01NS070024 · NINDS · JOHNS HOPKINS UNIVERSITY · PI QUINONES-HINOJOSA, ALFREDO · 2010 to 2014
$2.4MA novel microfluidic device to predict brain cancer prognosis and response to therapyR01CA216855 · NCI · MAYO CLINIC JACKSONVILLE · PI KONSTANTOPOULOS, KONSTANTINOS, QUINONES-HINOJOSA, ALFREDO · 2018 to 2022
$2.4MNanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer (Change of Organization Application)R01CA195503 · NCI · MAYO CLINIC JACKSONVILLE · PI GREEN, JORDAN, QUINONES-HINOJOSA, ALFREDO · 2016 to 2020
$1.9MBMP4 Engineered Mesenchymal Stem Cell Therapy for GlioblastomaR01CA183827 · NCI · MAYO CLINIC JACKSONVILLE · PI QUINONES-HINOJOSA, ALFREDO · 2015 to 2019
$1.9MOsteopontin-CD44 role in the malignancy of lateral ventricle infiltrating glioblastomaK01NS110930 · NINDS · MAYO CLINIC JACKSONVILLE · PI GUERRERO-CAZARES, HUGO · 2019 to 2023
$1.1MAdvanced Development of Desorption Electrospray Ionization Mass Spectrometry for Intraoperative Molecular Diagnosis of Brain Cancer using Pathology BiopsiesR33CA240181 · NCI · PURDUE UNIVERSITY · PI CHAICHANA, KAISORN LEE, COOKS, ROBERT GRAHAM · 2020 to 2021
$771kChemically produced neural progenitors as a delivery vehicle for anti-glioma therapyR43CA221490 · NCI · CELL REPROGRAMMING AND THERAPEUTICS, LLC · PI ALEXANIAN, ARSHAK R, QUINONES-HINOJOSA, ALFREDO · 2018 to 2018
$300kRole of SerpinA3 in the response of glioblastoma to cerebrospinal fluidR03NS109444 · NINDS · MAYO CLINIC JACKSONVILLE · PI GUERRERO-CAZARES, HUGO · 2018 to 2019
$236kHoward Hughes Medical InstituteNCI NIH HHS R01 CA183827NCI NIH HHS R01 CA195503NCI NIH HHS R01 CA200399NCI NIH HHS R01 CA216855NCI NIH HHS R33 CA240181NCI NIH HHS R43 CA221490NINDS NIH HHS K01 NS110930NINDS NIH HHS R01 NS070024NINDS NIH HHS R03 NS109444
Abstract
Glioblastoma (GBM) is the most common primary brain cancer in adults where tumor cell heterogeneity and sex differences influence clinical outcomes. Here, we functionally characterize three male and three female patient-derived GBM cell lines, identify protumorigenic BTICs, and create novel male and female preclinical models of GBM. Cell lines were evaluated on the following features: proliferation, stemness, migration, tumorigenesis, clinical characteristics, and sensitivity to radiation, TMZ, rh
Indexed as
AgedAnimalsBrain NeoplasmsCell Line, TumorCell ProliferationFemaleGlioblastomaHumansMaleMiceMiddle AgedNeoplastic Stem CellsSex CharacteristicsSurvival Analysis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.